Status:
COMPLETED
Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
Lead Sponsor:
Assiut University
Conditions:
Heart Failure
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
We hypothesize that Dapagliflozin could improve the diuretic response in diabetic patients with acute decompensated heart failure owing to its diuretic effect in addition to improvement of blood gluco...
Detailed Description
The study will include 100 diabetic patients type 2 patients who will be admitted to care unit with decompensated heart failure.50 patient will receive Dapagliflozin plus insulin (if needed) and Diure...
Eligibility Criteria
Inclusion
- Diabetic patient type 2 with history of chronic heart failure(HFrEF) ,there is no prespecified inclusion criterion with respect to heart failure etiology and/or ejection fraction.
Exclusion
- Other etiologies of fluid overload different from heart failure.
- Hyponatremia: Sodium level below 125mmol/l
- Unstable patients: acute coronary syndrome, cardiogenic shock .
- Patients requiring inotropic agents or renal dialysis.
- Pregnancy or breastfeeding period.
- sever hepatic disease
- GFR is less than 45 mL/min/1.73 m² .
- Patient with diabetic ketoacidosis or non ketotic hyperosmolar.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04385589
Start Date
May 1 2020
End Date
December 20 2020
Last Update
February 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Aswān, Egypt, 71515